Iovance Biotherapeutics, Inc. (IOVA)
7.275
-0.04
(-0.48%)
USD |
NASDAQ |
Nov 20, 10:00
Iovance Biotherapeutics Cash from Operations (Quarterly) : -4.47M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -4.47M |
| June 30, 2026 | -60.84M |
| March 31, 2026 | -72.07M |
| December 31, 2025 | -52.56M |
| September 30, 2025 | -78.70M |
| June 30, 2025 | -67.45M |
| March 31, 2025 | -103.69M |
| December 31, 2024 | -73.30M |
| September 30, 2024 | -58.97M |
| June 30, 2024 | -98.43M |
| March 31, 2024 | -122.28M |
| December 31, 2023 | -83.97M |
| September 30, 2023 | -84.08M |
| June 30, 2023 | -93.95M |
| March 31, 2023 | -99.82M |
| December 31, 2022 | -77.67M |
| September 30, 2022 | -63.65M |
| June 30, 2022 | -77.64M |
| March 31, 2022 | -73.80M |
| December 31, 2021 | -53.85M |
| September 30, 2021 | -57.69M |
| June 30, 2021 | -54.01M |
| March 31, 2021 | -62.39M |
| December 31, 2020 | -62.69M |
| September 30, 2020 | -40.52M |
| Date | Value |
|---|---|
| June 30, 2020 | -36.64M |
| March 31, 2020 | -65.29M |
| December 31, 2019 | -53.82M |
| September 30, 2019 | -42.18M |
| June 30, 2019 | -33.80M |
| March 31, 2019 | -29.09M |
| December 31, 2018 | -31.55M |
| September 30, 2018 | -27.93M |
| June 30, 2018 | -23.92M |
| March 31, 2018 | -17.85M |
| December 31, 2017 | -20.96M |
| September 30, 2017 | -21.45M |
| June 30, 2017 | -17.50M |
| March 31, 2017 | -18.80M |
| December 31, 2016 | -12.16M |
| September 30, 2016 | -12.21M |
| June 30, 2016 | -3.748M |
| March 31, 2016 | -4.552M |
| December 31, 2015 | -6.579M |
| September 30, 2015 | -3.843M |
| June 30, 2015 | -4.500M |
| March 31, 2015 | -3.459M |
| December 31, 2014 | -3.315M |
| September 30, 2014 | -1.729M |
| June 30, 2014 | -1.322M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AVITA Medical, Inc. | -0.6192M |
| Halozyme Therapeutics, Inc. | 258.27M |
| CareDx, Inc. | 12.72M |
| Xencor, Inc. | 2.642M |
| Merck & Co., Inc. | 6.558B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -134.64M |
| Cash from Financing (Quarterly) | 86.28M |
| Free Cash Flow | -216.16M |
| Free Cash Flow Per Share (Quarterly) | -0.0204 |
| Free Cash Flow to Equity (Quarterly) | -8.513M |
| Free Cash Flow to Firm (Quarterly) | -9.306M |
| Free Cash Flow Yield | -6.42% |